Log in
NASDAQ:CRSP

Crispr Therapeutics Stock Forecast, Price & News

$92.65
+2.49 (+2.76 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$87.52
Now: $92.65
$92.88
50-Day Range
$79.67
MA: $89.23
$109.83
52-Week Range
$32.30
Now: $92.65
$111.90
Volume1.14 million shs
Average Volume1.03 million shs
Market Capitalization$6.50 billion
P/E Ratio201.41
Dividend YieldN/A
Beta2.31
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Read More
Crispr Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-41-561-3277
Employees188

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$289.59 million
Cash Flow$1.12 per share
Book Value$17.02 per share

Profitability

Net Income$66.86 million

Miscellaneous

Market Cap$6.50 billion
Next Earnings Date10/26/2020 (Estimated)
OptionableOptionable
$92.65
+2.49 (+2.76 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

How has Crispr Therapeutics' stock price been impacted by Coronavirus?

Crispr Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRSP stock has increased by 114.1% and is now trading at $92.65.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Crispr Therapeutics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Crispr Therapeutics
.

When is Crispr Therapeutics' next earnings date?

Crispr Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Crispr Therapeutics
.

How were Crispr Therapeutics' earnings last quarter?

Crispr Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings results on Monday, July, 27th. The company reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.95) by $0.35. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $19.77 million. Crispr Therapeutics had a return on equity of 2.35% and a net margin of 6.77%. The firm's revenue was down 86.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.01) EPS.
View Crispr Therapeutics' earnings history
.

What price target have analysts set for CRSP?

17 analysts have issued twelve-month price targets for Crispr Therapeutics' stock. Their forecasts range from $31.00 to $140.00. On average, they expect Crispr Therapeutics' share price to reach $104.25 in the next year. This suggests a possible upside of 12.5% from the stock's current price.
View analysts' price targets for Crispr Therapeutics
.

Who are some of Crispr Therapeutics' key competitors?

What other stocks do shareholders of Crispr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

Who are Crispr Therapeutics' key executives?

Crispr Therapeutics' management team includes the following people:
  • Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)
  • Dr. Samarth Kulkarni, CEO & Director (Age 40)
  • Mr. Michael John Tomsicek, Chief Financial Officer (Age 53)
  • Dr. Tony W. Ho, Head of R&D and Exec. VP
  • Dr. N. Anthony Coles Jr., Sr. Advisor (Age 59)

When did Crispr Therapeutics IPO?

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Crispr Therapeutics' stock symbol?

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are Crispr Therapeutics' major shareholders?

Crispr Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Carnegie Capital Asset Management LLC (0.13%), Ipswich Investment Management Co. Inc. (0.04%), Capital Investment Advisory Services LLC (0.03%), Teamwork Financial Advisors LLC (0.01%), Hamilton Lane Advisors LLC (0.01%) and Concorde Asset Management LLC (0.01%). Company insiders that own Crispr Therapeutics stock include Bradley J Phd Bolzon, Kurt Von Emster, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Tony W Ho and Vertex Pharmaceuticals (Europe.
View institutional ownership trends for Crispr Therapeutics
.

Which institutional investors are selling Crispr Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC, Ipswich Investment Management Co. Inc., Capital Investment Advisory Services LLC, Carnegie Capital Asset Management LLC, Resources Investment Advisors LLC., Flagship Harbor Advisors LLC, McGuire Investment Group LLC, and Rikoon Group LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Bradley J Phd Bolzon, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for Crispr Therapeutics
.

Which institutional investors are buying Crispr Therapeutics stock?

CRSP stock was purchased by a variety of institutional investors in the last quarter, including Teamwork Financial Advisors LLC, Hamilton Lane Advisors LLC, Concorde Asset Management LLC, Hershey Trust Co., Fieldpoint Private Securities LLC, Envestnet Asset Management Inc., NEXT Financial Group Inc, and Harel Insurance Investments & Financial Services Ltd..
View insider buying and selling activity for Crispr Therapeutics
.

How do I buy shares of Crispr Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Crispr Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $92.65.

How big of a company is Crispr Therapeutics?

Crispr Therapeutics has a market capitalization of $6.50 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.

What is Crispr Therapeutics' official website?

The official website for Crispr Therapeutics is www.crisprtx.com.

How can I contact Crispr Therapeutics?

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.